Clinical Effect of Somatostatin Combined with Diclofenac Sodium on Mild to Moderate Pancreatitis after Endoscopic Retrograde Cholangiopancreatography
Objective:To explore the clinical value of Somatostatin combined with Diclofenac Sodium in patients with pancreatitis after endoscopic retrograde cholangiopancreatography(ERCP).Method:A total of 86 patients who developed mild to moderate pancreatitis after ERCP and were admitted to Jiujiang NO.1 People's Hospital from March 2022 to March 2024 were divided into the conventional group and the study group by the random number table method,with 43 patients in each group.The conventional group was given conventional basic treatments such as anti-infection treatment,fluid supplementation,dietary control and gastrointestinal decompression,on this basis,the study group was treated with Somatostatin and Diclofenac Sodium.Clinical efficacy in the two groups was observed;serum amylase(AMS)and lipase were compared between two groups;changes in the levels of inflammatory factors[interleukin-6(IL-6)and C reactive protein(CRP)]and adverse reactions in both groups were recorded.Result:The clinical total effective rate of the conventional group[72.09%(31/43)]was significantly lower than that of the study group[90.70%(39/43)],the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in AMS and lipase indicators between the two groups(P>0.05);after treatment,the AMS and lipase indicators in both groups were decreased compared to those before treatment,and the decrease was more significant in the study group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in IL-6 level and CRP level between the two groups(P>0.05);after treatment,the levels of IL-6 and CRP in both groups were decreased compared to those before treatment,and the decrease was more significant in the study group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with conventional treatment,Somatostatin combined with Diclofenac Sodium is more effective to treat patients with pancreatitis after ERCP.It can significantly lower the levels of AMS,lipase and inflammatory factors in patients with pancreatitis,with good safety.
万方数据
维普
